Leerink Partners Resumes T2 Biosystems, Inc (TTOO) at Market Perform

November 10, 2016 6:45 AM EST
Get Alerts TTOO Hot Sheet
Price: $5.47 -1.8%

Rating Summary:
    2 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 10
Trade TTOO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners resumes coverage on T2 Biosystems, Inc (NASDAQ: TTOO) with a Market Perform rating and a price target of $5.00.

Analyst Puneet Souda commented, "While we view TTOO’s proprietary T2MR pathogen detection technology and large market opportunity favorably, we are inclined to stay on the sidelines until TTOO delivers consistently on instrument placements and strings together a series of solid quarters in line with Street expectations. And we believe the shares will work again if TTOO meets or exceeds the updated timeline and expectations laid out for the T2Bacteria pivotal clinical trial in 1Q17 and approval in 2H17. Recall that TTOO was initially planning for trial completion in 3Q16 and approval in early 2017."

For an analyst ratings summary and ratings history on T2 Biosystems, Inc click here. For more ratings news on T2 Biosystems, Inc click here.

Shares of T2 Biosystems, Inc closed at $6.31 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Add Your Comment